Jiangxi Sanxin MedtecLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Jiangxi Sanxin MedtecLtd şirketinin toplam hissedar öz sermayesi CN¥1.3B ve toplam borcu CN¥277.8M olup, bu da borç-öz sermaye oranını 20.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.2B ve CN¥829.9M dir. Jiangxi Sanxin MedtecLtd 'in FAVÖK'ü CN¥238.0M faiz karşılama oranı -30.8 dur. Şirketin CN¥404.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

20.9%

Borç/özkaynak oranı

CN¥277.82m

Borç

Faiz karşılama oranı	-30.8x
Nakit	CN¥404.12m
Eşitlik	CN¥1.33b
Toplam yükümlülükler	CN¥829.86m
Toplam varlıklar	CN¥2.16b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Investors Shouldn't Be Too Comfortable With Jiangxi Sanxin MedtecLtd's (SZSE:300453) Earnings

Oct 21

Jiangxi Sanxin Medtec Co.,Ltd.'s (SZSE:300453) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Oct 08

Returns Are Gaining Momentum At Jiangxi Sanxin MedtecLtd (SZSE:300453)

Sep 30

Jiangxi Sanxin MedtecLtd (SZSE:300453) Is Due To Pay A Dividend Of CN¥0.15

Apr 23

Jiangxi Sanxin Medtec Co.,Ltd.'s (SZSE:300453) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Apr 04

Concerns Surrounding Jiangxi Sanxin MedtecLtd's (SZSE:300453) Performance

Mar 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300453 'nin kısa vadeli varlıkları ( CN¥735.2M ) kısa vadeli yükümlülüklerini ( CN¥560.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 300453 şirketinin kısa vadeli varlıkları ( CN¥735.2M ) uzun vadeli yükümlülüklerini ( CN¥269.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300453 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 300453 'nin borç/öz sermaye oranı son 5 yılda 26.4% seviyesinden 20.9% seviyesine düştü.

Borç Kapsamı: 300453 'nin borcu işletme nakit akışı ( 163.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 300453 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Jiangxi Sanxin MedtecLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investors Shouldn't Be Too Comfortable With Jiangxi Sanxin MedtecLtd's (SZSE:300453) Earnings

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 3Q 2023)

Jiangxi Sanxin Medtec Co.,Ltd.'s (SZSE:300453) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Jiangxi Sanxin Medtec Co.,Ltd. to Report Q3, 2024 Results on Oct 15, 2024

Investor sentiment improves as stock rises 24%

Returns Are Gaining Momentum At Jiangxi Sanxin MedtecLtd (SZSE:300453)

Jiangxi Sanxin Medtec Co.,Ltd. Announces Interim Profit Distribution Plan to Be Implemented on A Shares for the Year 2024, Payable on 09 September 2024

Second quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.087 in 2Q 2023)

Jiangxi Sanxin Medtec Co.,Ltd. to Report First Half, 2024 Results on Jul 26, 2024

Now 23% undervalued

Jiangxi Sanxin MedtecLtd (SZSE:300453) Is Due To Pay A Dividend Of CN¥0.15

Dividend of CN¥0.15 announced

Jiangxi Sanxin Medtec Co.,Ltd.'s (SZSE:300453) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Jiangxi Sanxin Medtec Co.,Ltd. to Report Q1, 2024 Results on Apr 17, 2024

Concerns Surrounding Jiangxi Sanxin MedtecLtd's (SZSE:300453) Performance

Full year 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.36 in FY 2022)

Jiangxi Sanxin Medtec Co.,Ltd., Annual General Meeting, Apr 16, 2024

Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorates as stock falls 19%

Jiangxi Sanxin Medtec Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.074 in 3Q 2022)

Jiangxi Sanxin Medtec Co.,Ltd. to Report Q3, 2023 Results on Oct 21, 2023

Second quarter 2023 earnings released: EPS: CN¥0.087 (vs CN¥0.11 in 2Q 2022)

Jiangxi Sanxin Medtec Co.,Ltd. to Report First Half, 2023 Results on Aug 05, 2023

First quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.093 in 1Q 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.40 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.096 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.094 in 2Q 2021)

Jiangxi Sanxin Medtec Co.,Ltd. Announces Final Cash Dividend for 2021, Payable on 29 April 2022

High number of new directors

Jiangxi Sanxin Medtec Co.,Ltd. Announces Cash Dividend for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.095 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.094 (vs CN¥0.076 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.05 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.24 in FY 2019)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.45 (vs CN¥0.24 in FY 2019)

New 90-day high: CN¥18.61

Jiangxi Sanxin Medtec Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.92

Third quarter earnings released

Jiangxi Sanxin Medtec Co.,Ltd. to Report Q3, 2020 Results on Oct 19, 2020

New 90-day low - CN¥17.05

Earnings released

New 90-day high - CN¥24.73

Jiangxi Sanxin Medtec Co.,Ltd. to Report First Half, 2020 Results on Aug 19, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin